osteitis deformans: A disease of bone that initially results in the excessive resorption of bone (by osteoclasts) followed by the replacement of normal bone marrow with vascular and fibrous tissue.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
169 |
4. Check minimum number of eventsNone |
169 |
5. Include endpointsNone |
169 |
6. Filter based on genotype QC (FinnGen only) |
169 |
Control definitions (FinnGen only)
- Control exclude
- M13_OSTEOCHONDRO
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M86-M90
- Name in latin
- Osteitis deformans Paget
Similar endpoints
↥List of similar endpoints to
Paget disease
based on the number of shared cases.
Similar with more cases:
- Osteopathies and chondropathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1125 | 513 | 598 |
| Only index persons | 891 | 427 | 464 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 66.25 | 66.30 | 66.15 |
| Only index persons | 64.97 | 63.99 | 65.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 169 | 74 | 95 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 67.23 | 66.64 | 67.68 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 155
- Matched controls
- 1548
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M88.9
ICD-10 Finland
Paget disease of bone, unspecified
+∞
104.3
88
*
M88.88
ICD-10 Finland
Paget disease of other bones, other
+∞
85.5
74
*
M88.0
ICD-10 Finland
Paget disease of skull
+∞
20.2
19
*
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
37.9
16.2
20
6
M88
ICD-10 Finland
Paget disease of bone [osteitis deformans]
+∞
15.9
15
*
ZX120
NOMESCO Finland
Intravenous
5.8
12.5
37
79
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.2
10.7
76
354
7310A
ICD-9 Finland
Osteitis deformans and osteopathies associated with other disorders classified elsewhere, Osteitis deformans without mention of bone tumour
+∞
10.5
10
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
8.9
8.3
17
21
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.2
7.9
30
83
72199
ICD-8 Finland
Osteitis deformans
+∞
7.3
7
*
M79.0
ICD-10 Finland
Rheumatism, unspecified
8.9
7.0
14
17
NK6BN
NOMESCO Finland
Bone dynamic isotope examination
41.9
6.8
8
*
NF1AA
NOMESCO Finland
Hip X-ray examination
3.9
6.7
27
79
N02AX02
ATC
tramadol; systemic, rectal
2.4
6.7
85
515
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
4.8
6.5
21
49
NE1AA
NOMESCO Finland
Pelvis X-ray examination
4.3
6.4
23
60
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
37
21
22.28
46.86
1.9
1.1
—
—
—
0
0
49
100
6.49
24.54
2.8
3.7
72.0
90.7
ng/l
0.97
43
85
130
737
4.31
15.61
9.4
5.8
1.2
1.2
mmol/l
0.78
110
627
13
0
+∞
13.73
1.4
0.0
—
—
—
0
0
82
465
2.48
7.73
4.2
3.5
2.3
2.4
mmol/l
0.34
69
403
114
763
2.52
7.32
10.6
9.4
3.9
4.1
e9/l
0.50
98
669
22
64
3.80
6.83
2.7
1.3
—
—
—
0
0
129
951
2.51
6.15
4.5
3.7
15.3
15.0
pmol/l
0.61
121
836
95
618
2.23
6.07
6.6
4.3
35.1
34.7
g/l
0.26
86
572
17
47
3.91
5.64
2.6
3.9
83.5
201.4
mg/l
0.37
11
36
17
47
3.91
5.64
2.6
3.9
26.2
35.9
mg/l
0.35
11
37
22
83
2.90
4.53
1.6
1.9
—
—
—
0
0
126
1004
2.00
3.78
6.3
4.1
15.6
14.0
mm/h
0.39
114
909
13
40
3.44
3.71
2.4
2.1
1.8
1.7
mg/l
0.28
13
34
100
743
1.85
3.68
7.4
6.3
10.3
11.8
umol/l
1.15
93
698
103
776
1.84
3.58
3.3
2.9
56.2
49.1
u/l
0.20
93
706
77
542
1.77
3.27
4.0
3.2
—
—
—
0
0
42
250
1.90
3.04
3.2
2.9
3.0
1.9
e6/l
0.28
26
139
85
626
1.72
3.01
4.3
4.0
—
—
—
0
0
157
1400
2.71
2.97
25.8
18.4
139.7
139.7
mmol/l
0.13
157
1354
52
335
1.80
2.93
2.6
2.3
—
—
—
0
0
56
376
1.73
2.71
3.2
2.7
388.3
7956.6
umol/l
2.17
49
314
140
1212
1.90
2.58
6.3
4.5
1.9
2.0
mu/l
0.82
130
1068
38
231
1.83
2.56
35.7
28.0
1.7
1.4
inr
—
5
31
22
110
2.15
2.55
2.7
3.4
60.1
59.8
ml/min/173m2
0.01
11
51
60
418
1.68
2.51
3.5
3.3
0.5
0.3
e6/l
0.19
48
305
144
1263
1.95
2.47
23.8
15.0
73.9
73.5
ml/min/173m2
0.06
130
1023
155
1396
2.33
2.47
16.0
10.9
23.6
25.0
u/l
0.77
147
1331
60
424
1.64
2.36
2.9
2.2
65.1
57.1
u/l
0.89
55
386
45
296
1.71
2.31
5.1
3.2
2.4
2.5
mmol/l
0.66
38
262
20
101
2.11
2.26
2.4
2.0
9.9
12.4
nmol/l
0.70
20
87
157
1433
2.35
2.21
34.7
23.2
132.2
134.0
g/l
0.76
157
1402
79
605
1.57
2.20
3.5
4.0
25.6
40.4
ng/l
1.45
62
478
6
14
4.40
2.17
6.5
3.8
—
—
—
0
0
147
1313
1.92
2.17
5.7
5.5
2.6
2.6
mmol/l
0.08
132
1187
18
89
2.14
2.15
1.4
1.4
—
—
—
0
0
9
31
3.01
2.10
1.4
1.1
—
—
—
0
0
37
237
1.72
2.08
2.0
1.8
—
—
—
0
0
147
1318
1.89
2.07
22.8
15.5
22.6
27.1
mg/l
1.04
126
1063
85
675
1.52
1.94
4.7
3.8
0.0
0.0
estimate
0.00
15
127
12
52
2.41
1.92
1.5
1.6
—
—
—
0
0
21
116
1.93
1.89
3.0
1.7
291.9
388.4
nmol/l
1.07
21
106
5
12
4.26
1.83
1.4
1.2
—
—
—
0
0
8
29
2.84
1.81
1.9
1.2
—
—
—
0
0
39
263
1.63
1.80
3.2
2.7
1.3
0.9
e6/l
0.31
24
149
84
674
1.49
1.78
6.6
5.2
0.0
0.0
estimate
0.00
16
127
144
1300
1.73
1.75
5.6
5.1
6.1
6.1
mmol/l
0.38
127
1177
8
31
2.66
1.68
2.8
1.4
—
—
—
0
0
84
683
1.46
1.62
4.7
3.8
0.0
0.0
estimate
0.00
12
119
12
57
2.19
1.59
1.6
1.7
—
—
—
0
0
76
612
1.44
1.52
2.3
2.0
99.0
93.8
pmol/l
0.29
41
313
22
133
1.75
1.51
3.1
4.2
5.8
5.6
kpa
0.39
22
127
24
149
1.71
1.51
4.0
3.7
—
—
—
0
0
136
1225
1.56
1.50
4.7
4.3
1.4
1.2
mmol/l
1.72
119
1103
49
364
1.49
1.47
4.0
3.1
0.7
0.8
ug/l
0.19
39
262
78
635
1.42
1.45
5.9
5.4
2.3
2.8
ug/l
0.36
67
565
140
1273
1.58
1.43
5.2
4.9
4.5
4.4
mmol/l
0.27
125
1157
64
505
1.43
1.41
5.0
4.7
21.6
21.4
%
0.04
41
269
9
41
2.26
1.39
1.0
1.3
—
—
—
0
0
16
90
1.86
1.38
2.7
3.4
1.6
1.8
mmol/l
0.08
11
70
123
1093
1.46
1.37
24.5
17.3
39.8
38.7
%
1.24
73
700
9
42
2.21
1.36
1.6
1.1
—
—
—
0
0
64
509
1.41
1.34
3.1
2.9
1620.9
1409.0
ng/l
0.21
56
432
5
18
2.83
1.29
6.4
2.7
5.6
12.2
nmol/l
—
5
18
15
85
1.84
1.28
3.6
2.6
0.1
0.1
e6/l
0.26
15
85
16
94
1.78
1.22
1.6
1.5
—
—
—
0
0
64
517
1.38
1.20
5.1
4.2
—
—
—
0
0
29
206
1.49
1.08
1.4
1.2
39.3
44.8
iu/ml
—
7
70
137
1264
1.44
1.06
5.3
4.8
1.4
1.4
mmol/l
0.44
121
1139
24
165
1.53
1.04
2.1
1.8
—
—
—
0
0
42
324
1.39
1.02
1.8
1.7
1130.7
1185.2
nmol/l
0.10
32
246
136
1260
1.41
0.96
7.2
6.5
40.6
41.2
mmol/mol
0.41
126
1162
6
27
2.27
0.94
1.3
1.3
—
—
—
0
0
26
187
1.46
0.92
4.7
4.9
30.7
32.7
%
0.46
19
119
14
88
1.64
0.87
4.9
5.4
25.1
24.6
mmol/l
0.20
14
88
32
246
1.37
0.80
1.4
1.2
0.5
1.1
u/ml
—
6
71
26
194
1.40
0.77
1.5
1.2
29.6
18.5
u/ml
—
10
74
23
168
1.43
0.76
2.1
1.8
—
—
—
0
0
70
607
1.26
0.74
2.6
2.3
—
—
—
0
0
115
1064
1.25
0.66
30.9
19.4
14.1
13.8
%
1.36
115
1042
0
20
0.00
0.61
0.0
1.2
—
—
—
0
0
0
20
0.00
0.61
0.0
1.2
—
—
—
0
0
0
20
0.00
0.61
0.0
1.2
—
—
—
0
0
0
20
0.00
0.61
0.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
6
35
1.74
0.58
1.8
1.2
—
—
—
0
0
39
329
1.24
0.51
2.0
1.8
381.9
457.6
pmol/l
1.53
34
274
24
191
1.30
0.50
3.9
6.0
104.7
104.3
mmol/l
0.15
24
184
35
294
1.24
0.48
3.0
3.5
402.9
194.1
ng/l
0.36
29
248
10
68
1.50
0.48
1.9
1.7
0.2
5.0
ug/l
—
10
61
7
48
1.48
0.47
1.7
3.3
—
—
—
0
0
43
375
1.20
0.42
5.1
4.0
0.0
0.0
estimate
0.00
15
120
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
485.8
—
0
9
0
17
0.00
0.41
0.0
1.1
—
36.9
—
0
7
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
12
147
0.80
0.24
1.1
1.3
—
—
—
0
0
5
41
1.23
0.22
1.2
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
9.1
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
50
1.21
0.20
1.0
1.1
—
—
—
0
0
20
177
1.15
0.17
8.2
8.1
—
—
—
0
0
9
78
1.16
0.15
2.7
2.8
1.8
1.1
%
—
9
78
5
60
0.83
0.08
3.6
1.8
—
—
—
0
0
35
354
0.99
0.00
1.6
1.7
1.7
1.3
mmol/l
0.63
27
289
11
112
0.98
0.00
1.3
1.3
—
—
—
0
0
23
232
0.99
0.00
2.0
1.8
28.8
29.5
s
0.33
23
225
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
17.5
—
0
5
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_PAGET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_PAGET | 1.012 [0.76, 1.35] | 0.938 |
| Birth year | 0.999 [0.99, 1.01] | 0.783 |
During the follow-up period (1.1.1998 — 31.12.2019), 86 out of 317 females with M13_PAGET died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_PAGET | 1.119 [0.88, 1.43] | 0.362 |
| Birth year | 0.99 [0.98, 1.0] | 0.027 |
During the follow-up period (1.1.1998 — 31.12.2019), 132 out of 382 males with M13_PAGET died.
Mortality risk
Mortality risk for people of age
years, who have M13_PAGET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.097% | 0.261% |
| 5 | 0.632% | 1.405% |
| 10 | 1.7% | 3.576% |
| 15 | 3.327% | 6.476% |
| 20 | 6.058% | 11.352% |
Relationships between endpoints
↥Index endpoint: M13_PAGET – Paget disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data